SyntheX Labs operates in the biotechnology sector, focusing on drug discovery for previously undruggable proteins. Utilizing advanced genetics and synthetic biology, the company has developed proprietary platforms such as ToRPPIDO and ToRNeDO. These platforms use genetically engineered circuits for functional intracellular drug selection, which is more effective than traditional in vitro screening methods. SyntheX's technology allows for the discovery of novel compounds that can modulate protein interactions in unique ways, either orthosterically or allosterically. The primary clients include pharmaceutical companies and research institutions seeking innovative solutions for complex protein targets. SyntheX generates revenue through licensing its technology, partnerships, and collaborative research agreements. The company is positioned in the U.S. market but aims for global impact in the drug discovery landscape.

Keywords: drug discovery, synthetic biology, genetically engineered circuits, undruggable proteins, ToRPPIDO, ToRNeDO, protein interactions, E3 ligase, neosubstrate, biotechnology.